CRVS
CorvusBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The long case is that soquelitinib is gaining credibility across both immune disease and PTCL, with positive cohort-4 atopic dermatitis data, a newly initiated Phase 2 AD study, an ongoing registrational Phase 3 PTCL program, and runway into the second quarter of 2028 after the January financing [#PR-2026-01-20] [#PR-2026-03-12] [#10-K-2026-03-12].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -1.7.
What can break
Peer set is loose and forward visibility is still mostly milestone-monitoring rather than revenue-backed.
Momentum
79
Value
41
Sentiment
51
Setup hits (3d)
— · Net —
AI TargetsBase $16.00 · Bull $23.00 · Bear $9.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net —
Target $33.33
Why
Momentum79 · Δ7d -1.7
Value41 · Δ7d -0.1
Sentiment51 · Δ7d +1.7
So what
Strength-led posture. Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
79
26% active weight
Current posture
7d trendSoftening
Δ7d
-1.7
Δ21d
+59.8
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
51
34% active weight
Current posture
7d trendImproving
Δ7d
+1.7
Δ21d
-12.5
Why this grade
Composite grade B. Momentum 78.9 / Value 41.1 / Sentiment 50.9
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.25B
Beta
0.70
Shares Out
84.09M
P/E (TTM) · Derived
-77.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-35.59
Rev YoY
-
EPS YoY
+15.1%
Gross Margin
-
Op Margin
-
Net Debt
-$55.81M
Current Ratio
19.81
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology